Composition and method for administration of pharmaceutically active substances
Patent 5011678 Issued on April 30, 1991. Estimated Expiration Date: 
February 1, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 1, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesDrug administration Drug administration High-encapsulation liposome processing method Insulin administration using methyl and propyl paraben Patent #: 4789660 InventorsAssigneeApplicationNo. 305520 filed on 02/01/1989US Classes:424/45, Organic pressurized fluid514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/3, Insulin or derivative514/171, With additional active ingredient514/808, CALCITONIN OR DERIVATIVES514/866, DIABETES514/922, SIDE EFFECT REDUCTION BY INCORPORATION OF A SECOND DESIGNATED INGREDIENT514/947, Topical application514/951, POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE514/958, FOR SMOKING OR INHALING514/975CHARACTERIZED BY THE DESIGNATED SURFACTANT USEDExaminersPrimary: Rose, Shep K.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/12A61K 009/14 A61K 037/02 AbstractPharmaceutically active substances are administered in aerosol form by applying to a mucosal surface of the body a composition comprising a medically effective amount of a pharmaceutically active substance, a biocompatible amphiphilac steroid and a bicompatible (hydro/fluoro)carbon propellant.Other References
Field of SearchFOR SMOKING OR INHALINGTopical application Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI Insulin or derivative With additional active ingredient CALCITONIN OR DERIVATIVES DIABETES SIDE EFFECT REDUCTION BY INCORPORATION OF A SECOND DESIGNATED INGREDIENT Polyoxyalkylated compound containing POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE CHARACTERIZED BY THE DESIGNATED SURFACTANT USED Organic pressurized fluid | |
